GlassScriptPhysician profile
Trevor Marcotte
NPI 1649224734
$4,616.23
in general payments reported to CMS, 2019-2025
42 companies · $687 in 2025
The $687 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $533 · 2020: $335 · 2021: $973 · 2022: $526 · 2023: $933 · 2024: $629 · 2025: $687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,249.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $726.88 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $710.33 | 2019-2023 | Xarelto |
| Pfizer INC. | $407.15 | 2019-2025 | |
| Abbvie INC. | $349.05 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $315.90 | 2019-2023 | |
| Amgen INC. | $293.39 | 2019-2025 | Repatha, Otezla, Repatha |
| Antares Pharma, INC. | $176.13 | 2019-2023 | Nocdurna, Tlando, Xyosted |
| Abbott Laboratories | $164.51 | 2023-2025 | Freestyle Libre 3, Eterna, Freestyle Libre 2 |
| Lilly USA, LLC | $163.31 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $139.61 | 2023-2025 | Rexulti |
| Astellas Pharma US INC | $134.74 | 2019-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $123.88 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $98.12 | 2019-2025 | Arexvy, Shingrix |
| Exact Sciences Corporation | $79.27 | 2024-2025 | Cologuard Collection Kit |
| Allergan, INC. | $68.72 | 2019-2020 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trevor Marcotte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.